A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
NCT ID: NCT00109330
Last Updated: 2016-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
4116 participants
INTERVENTIONAL
2002-11-30
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
NCT00489970
Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine
NCT01262924
Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine
NCT00297856
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
NCT00319553
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years
NCT00346073
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Combined diphtheria, tetanus, acellular pertussis vaccine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Chronic administration of immunosuppressants.
* Administration of pre-school DTP vaccine within previous 5 years.
* Administration of Td booster within previous 10 years.
10 Years
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Mesa, Arizona, United States
GSK Investigational Site
Tempe, Arizona, United States
GSK Investigational Site
Jonesboro, Arkansas, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Escondido, California, United States
GSK Investigational Site
Fullerton, California, United States
GSK Investigational Site
Redondo Beach, California, United States
GSK Investigational Site
Rolling Hills Est, California, United States
GSK Investigational Site
Torrance, California, United States
GSK Investigational Site
Yorba Linda, California, United States
GSK Investigational Site
Boulder, Colorado, United States
GSK Investigational Site
Centennial, Colorado, United States
GSK Investigational Site
Golden, Colorado, United States
GSK Investigational Site
Middletown, Connecticut, United States
GSK Investigational Site
Norwich, Connecticut, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Bardstown, Kentucky, United States
GSK Investigational Site
New Bedford, Maine, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
Milford, Massachusetts, United States
GSK Investigational Site
Woburn, Massachusetts, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Whitehouse Station, New Jersey, United States
GSK Investigational Site
Rochester, New York, United States
GSK Investigational Site
Stony Brook, New York, United States
GSK Investigational Site
Chapel Hill, North Carolina, United States
GSK Investigational Site
Durham, North Carolina, United States
GSK Investigational Site
Lumberton, North Carolina, United States
GSK Investigational Site
Akron, Ohio, United States
GSK Investigational Site
Cleveland, Ohio, United States
GSK Investigational Site
University Heights, Ohio, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Sellersville, Pennsylvania, United States
GSK Investigational Site
Kingsport, Tennessee, United States
GSK Investigational Site
Bryan, Texas, United States
GSK Investigational Site
Georgetown, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Temple, Texas, United States
GSK Investigational Site
Salt Lake City, Utah, United States
GSK Investigational Site
West Jordan, Utah, United States
GSK Investigational Site
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Statistical Analysis Plan
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
776423/001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.